glp-1 medication weight loss timeline New Drugs for What Plan Sponsors Need to Know obesitymedicine #metabolichealth #glp1 #clinicaltrials #healthcareinnovation
Description
2023;83(7 Suppl):735735.36594876 [Google Scholar] 98.Leslie KK, Hagemann A, Thiel K, et al
Problems occurred more often in women, and more often in people ages 45-64
Semaglutide is the active ingredient in FDA-approved products for type 2 diabetes and chronic weight management
At the pancreatic level, GIPR provides an additive insulinotropic stimulus complementing GLP-1R-mediated effects
doi: 10.2337/dc20-2151
In 2021, it gained FDA approval for chronic weight management under the name Wegovy, representing a significant advancement in obesity treatment options
